INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Grant or awardVerified data

Kumar Neil reported MAZE

Director · Maze Therapeutics, Inc. · Maze Therapeutics, Inc. — Stock Option (Right to Buy)

Side
A
Value
—
Shares
33.4K
Price
—
Executed
Mar 27, 2026
Disclosed
Mar 31, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Mar 27 executedMar 31, 2026 disclosed

MAZE · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MAZE

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    CV
    Coloma Jason VDirector, Chief Executive Officer
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$166K
    5,345 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    6
    CV
    Coloma Jason VDirector, Chief Executive Officer
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$10K
    336 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    CV
    Coloma Jason VDirector, Chief Executive Officer
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$799K
    26.6K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    CV
    Coloma Jason VDirector, Chief Executive Officer
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$68K
    2,257 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    3
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$69K
    6,643 sh
    		Oct 29, 2026Oct 30, 2026
    traded Oct 29, 2026
    		+1dSEC FORM 4

    Evidence

    0
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    857 sh
    		Oct 29, 2026Oct 30, 2026
    traded Oct 29, 2026
    		+1dSEC FORM 4

    Evidence

    0
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$8,930
    857 sh
    		Oct 29, 2026Oct 30, 2026
    traded Oct 29, 2026
    		+1dSEC FORM 4

    Evidence

    10
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$241K
    7,500 sh
    		Oct 29, 2026Oct 30, 2026
    traded Oct 29, 2026
    		+1dSEC FORM 4

    Evidence

    0
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    6,643 sh
    		Oct 29, 2026Oct 30, 2026
    traded Oct 29, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BH
    Bernstein HaroldPresident, R&D & CMO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    16.1K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    21
    BH
    Bernstein HaroldPresident, R&D & CMO
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$435K
    16.1K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BH
    Bernstein HaroldPresident, R&D & CMO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$168K
    16.1K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    0
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    7,500 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    10
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$203K
    7,500 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    3
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$78K
    7,500 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    31
    BH
    Bernstein HaroldPresident, R&D & CMO
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$255K
    9,705 sh
    		Sep 4, 2026Sep 8, 2026
    traded Sep 4, 2026
    		+4dSEC FORM 4

    Evidence

    29
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Open-market sale
    		SELL$11K
    391 sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    32
    CP
    Courtney PhillipsGC and Corp. Secretary
    MAZEMaze Therapeutics, Inc.
    Open-market sale
    		SELL$567
    22 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    36
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Open-market sale
    		SELL$83K
    3,207 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    40
    BH
    Bernstein HaroldPresident, R&D & CMO
    MAZEMaze Therapeutics, Inc.
    Open-market sale
    		SELL$133K
    5,130 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001742485-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 27, 2026
    Published
    Mar 31, 2026
    Ingested by INSIDER
    Nov 5, 04:08 UTC
    Last re-read
    Nov 5, 04:08 UTC

    Extracted facts

    Filer
    Kumar Neil
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Maze Therapeutics, Inc. — Stock Option (Right to Buy)
    Ticker
    MAZE
    Shares
    33.4K
    Price per share
    $0
    Execution date (reported)
    Mar 27, 2026
    Owned after transaction
    33.4K shares
    Days from execution to publication
    4

    What this establishes

    Kumar Neil filed this Form 4 reporting a grant or award of MAZE on Mar 27, 2026. It became public on Mar 31, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Kumar Neilcik:0001742485
    Issuer
    Maze Therapeutics, Inc.cik:0001842295

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.